Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OXALIPLATIN Cause Electrocardiogram qt prolonged? 98 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 98 reports of Electrocardiogram qt prolonged have been filed in association with OXALIPLATIN (Oxaliplatin). This represents 0.2% of all adverse event reports for OXALIPLATIN.

98
Reports of Electrocardiogram qt prolonged with OXALIPLATIN
0.2%
of all OXALIPLATIN reports
1
Deaths
52
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From OXALIPLATIN?

Of the 98 reports, 1 (1.0%) resulted in death, 52 (53.1%) required hospitalization, and 24 (24.5%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OXALIPLATIN. However, 98 reports have been filed with the FAERS database.

What Other Side Effects Does OXALIPLATIN Cause?

Diarrhoea (4,963) Nausea (4,250) Neuropathy peripheral (3,662) Off label use (3,603) Neutropenia (3,391) Vomiting (3,383) Disease progression (3,370) Thrombocytopenia (2,886) Dyspnoea (2,779) Pyrexia (2,269)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which OXALIPLATIN Alternatives Have Lower Electrocardiogram qt prolonged Risk?

OXALIPLATIN vs OXAPROZIN OXALIPLATIN vs OXAZEPAM OXALIPLATIN vs OXCARBAZEPINE OXALIPLATIN vs OXITRIPTAN OXALIPLATIN vs OXOMEMAZINE

Related Pages

OXALIPLATIN Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged OXALIPLATIN Demographics